Long-term treatment with chlorpromazine and haloperidol but not with sulpiride and clozapine markedly elevates neuropeptide Y-like immunoreactivity in the rat hypothalamus

Neuropeptides

Volumn 30, Issue 5, 1996, Pages 471-478

  Obuchowicz, E ^a,b  

^a UNIVERSITY OF SILESIA   (Poland)

^b Department of Clinical Pharmacology ^*  (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROPEPTIDE Y; PRAZOSIN; QUINPIROLE; SULPIRIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPOTHALAMUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0029970781     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(96)90012-8     Document Type: Article

References (34)

1. Williams G, Steel J H, Polak J M, Bloom S R. Neuropeptide Y in the hypothalamus. In: Mutt V, Hökfelt T, Fuxe K, Lundberg J M, eds. Neuropeptide Y. New York: Raven Press, 1989: 243-251.
2. Dumont Y, Fournier A, Pierre S St, Quirion R. Comparative characterization and autoradiographic distribution of neuropeptide Y receptor subtypes in the rat brain. J Neurosci 1993; 13: 73-86.
3. Leibowitz S F. Brain neuropeptide Y: an integrator of endocrine, metabolic and behavioral processes. Brain Res Bull 1991; 27: 333-337.
4. Stanley B G. Neuropeptide Y in multiple hypothalamic sites controls eating behavior, endocrine, and autonomic systems for body energy balance. In: Colmers W F, Wahlestedt C eds. The Biology of Neuropeptide Y and Related Peptides. Totowa, N J; Humana Press, 1993: 457-509.
5. Li S, Pelletier G. The role of dopamine in the control of neuropeptide Y neurons in the rat arcuate nucleus. Neurosci Lett 1986; 69: 74-77
6. Pelletier G, Simard J. Dopamine regulation of preproNPY mRNA levels in the rat arcuate nucleus. Neurosci Lett 1991; 127: 96-98.
7. Tessel R E, DiMaggio D A, O'Donohue T L. Amphetamineinduced changes in immunoreactive NPY in rat brain, pineal gland and plasma. Peptides 1985; 6: 219-224.
8. 13-36 on the brain monoaminergic systems of the rat. J Neural Transm [Gen Sect] 1990; 79: 193-208.
9. Myers R D, Lankford M F, Paez X. Norepinephrine, dopamine and 5-HT release from perfused hypothalamus of the rat during feeding induced by neuropeptide Y. Neurochem Res 1992; 17: 1123-1132.
10. Gillard E R, Dang D Q, Stanley B G. Evidence that neuropeptide Y and dopamine in the perifornical hypothalamus interact antagonistically in the control of food intake. Brain Res 1993; 628: 128-136.
11. Gunnet J W, Moore K. Neuroleptics and neuroendocrine function. Ann Rev Pharmacol Toxicol 1988; 28: 347-366.
12. Leibowitz S F, Rossakis C. Pharmacological characterization of perifornical hypothalamic dopamine receptors mediating feeding inhibition in the rat. Brain Res 1979; 172: 115-130.
13. Parada M A, Hernandez L, Hoebel B G. Sulpiride injections in the lateral hypothalamus induce feeding and drinking in rats. Pharmacol Biochem Behav 1988; 30: 917-923.
14. Rupniak N M J, Kilpatrick G, Hall M D, Jenner P, Marsden C D. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. Psychopharmacology 1984; 84: 512-519.
15. Klein M, Cooper Th B, Musacchio J M. Effects of haloperidol and reduced haloperidol on binding to σ sites. Eur J Pharmacol 1994; 254: 239-248.
16. Snyder S H, Largent B L. Receptor mechanisms in antipsychotic drug action: focus on sigma receptors. J Neuropsychiatry Clin Neurosci 1989; 1: 7-15.
17. Walker J M, Matsumoto R R, Bowen W D, Gans D L, Jones K D, Walker F O. Evidence for a role of haloperidol-sensitive sigma'opiate' receptors in the motor effects of antipsychotic drugs. Neurology 1988; 38: 961-965.
18. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 1993; 265: 498-508.
19. Reynolds G P. Developments in the drug treatment of schizophrenia. Trends Pharmacol Sci 1992; 13: 116-121.
20. Coward D M. General pharmacology of clozapine. Br J Psych 1992; 160 (suppl 17): 5-11.
21. Hals P A, Hall H, Dahl S G. Phenothiazine drug metabolites: dopamine D2 receptor, alpha 1- and alpha 2-adrenoceptor binding. Eur J Pharmacol 1986; 125: 373-381.
22. Bowen W D, Moses E L, Tolentino P J, Walker J M. Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors. Eur J Pharmacol 1990; 177: 111-118.
23. Öhman R, Larsson M, Nilsson IM, Engel J, Carlsson A. Neurometabolic and behavioral effects of haloperidol in relation to drug levels in serum and brain. Naunyn-Schmiedeberg's Arch Pharmacol 1977; 299: 105-114.
24. Itzhak Y, Stein I. Regulation of sigma receptors and responsiveness to guanine nucleotides following repeated exposure of rats to haloperidol: further evidence for multiple sigma binding sites. Brain Res 1991; 566: 166-172.
25. Roman F J, Martin B, Junien J L. In vivo interaction of neuropeptide Y and peptide YY with σ receptor sites in the mouse brain. Eur J Pharmacol 1993; 242: 305-307.
26. Jackson D M, Westlind-Danielsson A. Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol Ther 1994; 64: 291-369.
27. Kakigi T, Maeda K. Effects of serotoninergic agents on regional concentration of somatostatin and neuropeptide Y-like immunoreactivities in the rat brain. Brain Res 1992; 599: 45-50.
28. Dryden S, Wang Q, Prankish H, Pickavance L, Williams G. The serotonin (5HT) antagonist methysergide increases neuropeptide Y (NPY) synthesis and secretion in the hypothalamus of the rat. Brain Res 1995; 699: 12-18.
29. Ciarleglio A E, Beinfeld M C, Westfall T C. Pharmacological characterization of the release of neuropeptide Y-like immunoreactivity from the rat hypothalamus. Neuropharmacology 1993; 32: 819-825.
30. Seeman Ph, Van Tol H H M. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994; 15: 264-270.
31. Härfstrand A, Eneroth P, Agnati L F, Fuxe K. Further studies on the effects of central administration of neuropeptide Y on neuroendocrine function in the male rat: relationship to hypothalamic catecholamines. Reg Peptides 1987; 17: 167-179.
32. McCann S M, Rettori V, Milenkovic L, Riedel M, Aguila C, McDonald J K. The role of neuropeptide Y (NPY) in control of anterior pituitary hormone release in the rat. In: Mutt V, Fuxe K, Hökfelt T, Lundberg J M, eds. Neuropeptide Y. New York: Raven Press, 1989: 215-227.
33. Hanson E S, Dallman M F. Neuropeptide Y (NPY) may integrate responses of hypothalamic feeding systems and the hypothalamo-pituitary-adrenal axis. J Neuroendocrinol 1995; 17: 273-279.
34. Gudelsky G A, Koenig J I, Simonovic M, Koyama T, Ohmori T, Meltzer HY. Differential effects of haloperidol, clozapine and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat. J Neural Transm 1987; 68: 227-240.